Bristol-Myers Squibb (BMY) Tops Q2 EPS by 2c

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.93, $0.02 better than the analyst estimate of $1.91. Revenue for the quarter came in at $11.7 billion versus the consensus estimate of $11.33 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus of $7.46.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
• Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
• Novartis hikes full-year guidance as Q1 results exceed estimates, shares pop